Soluble Guanylate Cyclase Stimulators in Heart Failure
Open Access
- 6 September 2021
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 13 (9)
Abstract
Heart failure has a high global burden of morbidity and mortality. Despite significant advances in medical management of heart failure, the prognosis remains poor. This justifies the search for newer therapeutic agents. Recently, soluble guanylate stimulators have demonstrated favorable results in clinical trials. This article aims to summarize the guanylate cyclase signaling pathway, the role of soluble guanylate cyclase stimulators in heart failure, and data from recent clinical trials of these drugs. We concluded that soluble guanylate cyclase stimulators have significant benefits in reducing hospitalizations in patients with heart failure with reduced ejection fraction that are at high risk of cardiovascular events. There appears to be no benefit of these drugs in patients with heart failure with preserved ejection fraction.Keywords
This publication has 27 references indexed in Scilit:
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Heart Journal, 2015
- Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1)Chest, 2014
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive SummaryCirculation, 2013
- Effect of Nesiritide in Patients with Acute Decompensated Heart FailureNew England Journal of Medicine, 2011
- Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trialsEuropean Heart Journal, 2009
- Nitric Oxide and Peroxynitrite in Health and DiseasePhysiological Reviews, 2007
- Nitric Oxide and Cyclic GMP in Cell Signaling and Drug DevelopmentNew England Journal of Medicine, 2006
- cGMP signalling: from bench to bedsideEMBO Reports, 2006
- Short-term Intravenous Milrinone for Acute Exacerbation of Chronic Heart FailureA Randomized Controlled TrialJAMA, 2002